PMID- 23485176
OWN - NLM
STAT- MEDLINE
DCOM- 20130927
LR  - 20181202
IS  - 1873-2534 (Electronic)
IS  - 0165-2427 (Linking)
VI  - 153
IP  - 1-2
DP  - 2013 May 15
TI  - Development of an in vitro model system for studying the interaction of Equus 
      caballus IgE with its high-affinity receptor FcvarepsilonRI.
PG  - 10-6
LID - S0165-2427(13)00029-9 [pii]
LID - 10.1016/j.vetimm.2013.01.008 [doi]
AB  - The binding of immunoglobulin E (IgE) to its high-affinity receptor (FcvarepsilonRI) is 
      the central protein interaction in IgE-mediated allergic reactions. The 
      cross-linking of the IgE/FcvarepsilonRI complex, through cognate allergens, on the surface 
      of mast cells and basophil cells results in mediator release, and thus leads to 
      the symptoms of type I hypersensitivity responses in mammals. To develop a 
      baseline value for subsequent equine anti-allergy drug and vaccine research, the 
      interaction of equine IgE with its high-affinity FcvarepsilonRI receptor was investigated 
      following the cloning and expression of equine IgE with specificity for NIP-HSA 
      (4-hydroxy-5-iodo-3-nitrophenylacetic acid conjugated to human serum albumin). 
      Receptor recognition and effector functions were assessed in Rat Basophil 
      Leukemia (RBL-2H3.1) cells transfected with the alpha chain of equine and canine 
      FcvarepsilonRI. Results obtained showed that the equine FcvarepsilonRI receptor recognizes both 
      equine and canine IgE and supports similar beta-hexosaminidase release levels from 
      RBL cells transfected with equine FcvarepsilonRI, peaking at 36.68% at 100ngml(-1) antigen 
      and 32.00% at 100ngml(-1) antigen respectively. Furthermore, the binding kinetics 
      of the equine IgE to the equine FcvarepsilonRI receptor and the canine IgE to the same 
      receptor was measured to be KA=6.33x10(9)M(-1) and KA=1.84x10(9)M(-1) 
      respectively. This research established basic reagents and vitro assay systems to 
      underpin the development of rational therapeutic intervention strategies to 
      combat equine allergic manifestations.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
FAU - Sabban, Sari
AU  - Sabban S
AD  - The Krebs Institute for Biomolecular Research, Department of Molecular Biology 
      and Biotechnology, The University of Sheffield, Sheffield S10 2TN, UK. 
      sari.sabban@gmail.com
FAU - Ye, Hongtu
AU  - Ye H
FAU - Helm, Birgit
AU  - Helm B
LA  - eng
PT  - Journal Article
DEP - 20130211
PL  - Netherlands
TA  - Vet Immunol Immunopathol
JT  - Veterinary immunology and immunopathology
JID - 8002006
RN  - 0 (Receptors, IgE)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 3.2.1.52 (beta-N-Acetylhexosaminidases)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Dogs
MH  - Horses/*immunology
MH  - Immunoglobulin E/*metabolism
MH  - Rats
MH  - Receptors, IgE/*metabolism
MH  - Surface Plasmon Resonance
MH  - beta-N-Acetylhexosaminidases/metabolism
EDAT- 2013/03/15 06:00
MHDA- 2013/09/28 06:00
CRDT- 2013/03/15 06:00
PHST- 2012/04/25 00:00 [received]
PHST- 2012/12/29 00:00 [revised]
PHST- 2013/01/16 00:00 [accepted]
PHST- 2013/03/15 06:00 [entrez]
PHST- 2013/03/15 06:00 [pubmed]
PHST- 2013/09/28 06:00 [medline]
AID - S0165-2427(13)00029-9 [pii]
AID - 10.1016/j.vetimm.2013.01.008 [doi]
PST - ppublish
SO  - Vet Immunol Immunopathol. 2013 May 15;153(1-2):10-6. doi: 
      10.1016/j.vetimm.2013.01.008. Epub 2013 Feb 11.